Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Vomiting 13Nausea 13Neoplasms 8Hematologic Neoplasms 5Anorexia 4Cachexia 3Breast Neoplasms 3Weight Loss 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Multiple Myeloma 2Lung Neoplasms 2Advanced Cancer 2Testicular Neoplasms 1Solid Tumor Patients Receiving High Emetic Risk Multi-day Chemotherapy 1Sedentary Behavior 1Radiation Injuries 1Prosthesis Failure 1Postoperative Nausea and Vomiting 1Pain 1Opioid-Related Disorders 1Nutrition Disorders 1Neoplasms, Plasma Cell 1Neoplasms, Germ Cell and Embryonal 1Muscular Atrophy 1Multiple Endocrine Neoplasia Type 1 1Lymphoma 1Insulin Resistance 1Hyperlipidemias 1Hyperglycemia 1

Interventions

Cisplatin 13Etoposide 11Paclitaxel 8Cyclophosphamide 7Carboplatin 7Ifosfamide 6etoposide phosphate 5Granulocyte Colony-Stimulating Factor 5Gemcitabine 5pembrolizumab 4fludarabine 4Sirolimus 4Bleomycin 4fludarabine phosphate 3Sunitinib 3Oxaliplatin 3Mesna 3Melphalan 3Filgrastim 3Drug Therapy 3Brentuximab Vedotin 3Bevacizumab 3Automobiles 3130-nm albumin-bound paclitaxel 3tremelimumab 2sodium thiosulfate 2ribociclib 2pralsetinib 2pegfilgrastim 2lutetium Lu 177 dotatate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms, Germ Cell and Embryonal × Olanzapine × Clear all
NCT03960151 2019-05-22

Rolapitant Plus Olanzapine in Multiday Cisplatin Chemotherapy

Hoosier Cancer Research Network

Phase 2 Withdrawn

Neoplasms, Germ Cell and Embryonal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡